Summary
Two new lab tests—one using blood, the other spinal fluid—aim to detect Alzheimer’s impact on memory, rather than just amyloid plaques.
Researchers say amyloid can accumulate without causing symptoms, so new biomarkers offer a clearer picture.
One test measures MTBR-tau243, a tau protein linked to memory loss, while another tracks two synapse-related proteins that predict cognitive decline up to 20 years in advance.
These NIH-funded tools could help doctors determine who would benefit from treatment and identify early-stage Alzheimer’s before symptoms appear.
You must log in or register to comment.
So its a fuckup of proteins? Isn’t that a fixable problem with genetic modification?
Maybe. Maybe not. Maybe the research is defunded and we never find out.
